The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker..
Share this article
Analysis
Neutral
With Zepbound approved for sleep apnea, Lilly spends up to $7.8 billion for a company with a narcolepsy drug
Mar 31, 2026 14:45 UTC
Related Articles
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.